Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

'What Is Microbiologic Success?': Rare Lung Infection Is Microcosm Of Antibiotic Development Challenges

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is working hard on expanded access program for patients with non-tuberculous mycobacterial (NTM) lung infections; there is no approved drug for the condition in part because of the difficulty in defining trial endpoints.

Advertisement

Related Content

Congressional ‘Cures’ Debate Shifts To FDA Funding

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register